BrainSee
CABHI supported BrainSee through clinical validation, securing Baycrest itself as a trial site along with Hamilton Health Sciences and UHN.
This means BrainSee’s early detection technology was tested, validated, and advanced through Baycrest’s research ecosystem, using Baycrest clinicians, researchers, and infrastructure.
CABHI also helps the company advance business development and adoption opportunities.
Xandar Kardian
CABHI supported Xandar Kardian through its MC2 program, which provides funding, mentorship, scientific support, and connections to investors and real world adopters.
CABHI helped the company refine its early intervention technology, expand into new care settings, and accelerate adoption.
This technology is part of Baycrest’s broader innovation pipeline for dementia care.